Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMPN 2026 | Insights into the current role of ropeginterferon in the ET treatment landscape

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the approval of ropeginterferon for essential thrombocythemia (ET), highlighting its broad label for use in patients with ET who need therapy, including frontline or second-line options. Dr Masarova advises clinicians to consider ropeginterferon for patients who have failed frontline therapies and for young patients or those seeking more than just count control. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So we had a couple approvals for ET patients this year, and ropeginterferon was one of them. It’s a pegylated interferon alpha that has been studied in two studies in patients with essential thrombocythemia following its previous approval on polycythemia vera patients. One of them was EXCEED-ET and one of them was SURPASS-ET. So the approval was based on both of these studies and actually has a pretty broad label used in patients with essential thrombocythemia in the need for therapy...

So we had a couple approvals for ET patients this year, and ropeginterferon was one of them. It’s a pegylated interferon alpha that has been studied in two studies in patients with essential thrombocythemia following its previous approval on polycythemia vera patients. One of them was EXCEED-ET and one of them was SURPASS-ET. So the approval was based on both of these studies and actually has a pretty broad label used in patients with essential thrombocythemia in the need for therapy. That includes frontline or second-line therapies as well as patients that would be high risk or historically low risk. And that came from the design of the studies where SURPASS-ET was a second-line study. There was primarily enrolling patients in the Asian region, less of Native Americans or Canadians, and then basically had a comparator arm anagrelide. So it was Phase III randomized where patients previously failed and exposed to hydroxyurea or any frontline would be eligible to enroll. And then ropeg interferon showed sustained improvements in responses where primary endpoints was durable, complete hematologic response, and lack of progression of splenomegaly symptoms. So that was achieved on ropeg in about 43% of patients and in 6% of patients on anagrelide. And that followed study that was named EXCEED-ET That actually did include only North American region patients and not patients with a single-arm ropeg interferon with the same schedule. That study included patients refractory to hydroxyurea, so second line, similarly to previous trial, but also patients that would be a low risk or patients that need therapy, but not having a standard definitions of high risk. So that means that supporting the approval across the broad patients with ET that need treatments, which is kind of nice for the landscape because we are often missing on patients that would not be historically high risk, but had a therapy needs because of the symptoms, splenomegaly, and control counts. And that is actually a matter of fitting the landscape. So the advice for the clinical practitioner would be, actually, ropeg interferon has consistently showed superior efficacy over second-line therapy. So definitely, if patients fail front-line therapies, ropeginterferon, if not contraindicated, should be suggested and considered for any patient population. They don’t have a clear contraindication. And then also for a specifically young population where ropeginterferon has been historically used, and also patients that actually want to do more than just controlling the blood counts, because obviously ropeg interferon is also some other agents rolling in a space, have a better ability to control the disease itself, meaning we have seen molecular responses even that early, as in 12 months above of the SURPASS-ET and EXCEED-ET study, that it was achieving about one-third of the patient. That’s remarkable mark saying that the study had such a short follow-up. So a follow-up will come up with a longer time. That’s the most important for decision-making for using it frontline or lower risk patients. However, there are already some data from other population, especially PV. So just watching up on the space to see how the agent evolves and kind of more paying attention and learning how to use the agent because it’s a subcutaneous version of therapy, not orals. And it comes with some side effect profile that has to be monitored and watched for.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.